Analyst consensus rating
NeuroSense Therapeutics Analyst Rating: Strong Buy
Direct answer
NeuroSense Therapeutics's consensus rating is Strong Buy.
4 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $6.88.
Forecast evidence checked September 8, 2026.
Get free NeuroSense Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $0.42
- Average price target
- $6.88
- High price target
- $9.00
- Low price target
- $3.00
- Low target gap
- +617.5%
- Target upside
- +1,544.3%
- High target gap
- +2,052.6%
- Target range width
- 1,435.1%
- Consensus rating
- Strong Buy
- Analysts
- 4
- Evidence date
- September 8, 2026
- Valid through
- September 15, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for NeuroSense Therapeutics?
NeuroSense Therapeutics has a verified Strong Buy consensus. The same dataset has an average price target of $6.88.
How far are NeuroSense Therapeutics's low and high targets from the recorded price?
The low target implies +617.5%, while the high target implies +2,052.6%.
How many analysts are included in NeuroSense Therapeutics's consensus?
The verified consensus includes 4 analysts.
How is NeuroSense Therapeutics's target upside or downside calculated?
The average target of $6.88 is divided by the recorded price of $0.42, then one is subtracted to produce +1,544.3%. This does not guarantee a future return.
When was NeuroSense Therapeutics's analyst forecast verified?
The data was verified on 2026-09-08. The dataset is valid through 2026-09-15.